Methadone Tied to Lower Risk for Discontinuation Versus Buprenorphine/Naloxone
By Lori Solomon HealthDay Reporter
FRIDAY, Oct. 18, 2024 -- Receipt of methadone for opioid use disorder is associated with a lower risk for treatment discontinuation compared with buprenorphine/naloxone, according to a study published online Oct. 17 in the Journal of the American Medical Association.
Bohdan Nosyk, Ph.D., from Simon Fraser University in Burnaby, British Columbia, Canada, and colleagues assessed the risk for treatment discontinuation and mortality among individuals receiving buprenorphine/naloxone versus methadone for the treatment of opioid use disorder. The analysis included 30,891 incident adult users (2010 to 2020) who were not incarcerated, pregnant, or receiving palliative cancer care.
The researchers found that incident users of buprenorphine/naloxone had a higher risk for treatment discontinuation versus methadone in initiator analyses (88.8 versus 81.5 percent discontinued at 24 months; adjusted hazard ratio [HR], 1.58). Similar results were found when evaluated at optimal dose in a per-protocol analysis (42.1 versus 30.7 percent; adjusted HR, 1.67). Mortality while receiving treatment showed ambiguous results in per-protocol analyses (incident users: 0.08 versus 0.13 percent mortality at 24 months; adjusted HR, 0.57; 95 percent confidence interval [CI], 0.24 to 1.35; prevalent users: 0.08 versus 0.09 percent; adjusted HR, 0.97; 95 percent CI, 0.54 to 1.73). Similar results were seen after the introduction of fentanyl and across patient subgroups.
“As the use of more potent synthetic opioids continues to increase in North America and elsewhere, clinical guidelines for all aspects of the treatment of people with opioid use disorders require reconsideration to reduce the risk of discontinuation of treatment,” the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
Discontinuation of Medical Cannabis Common in Musculoskeletal Pain
TUESDAY, Aug. 26, 2025 -- A number of patients with musculoskeletal pain discontinue medical cannabis (MC) within one year, with many discontinuing within the first three months...
AAP Offers Guidance for Tapering of Opioids to Prevent Withdrawal in Children
TUESDAY, Aug. 19, 2025 -- A plan for tapering opioids should be developed to minimize withdrawal symptoms in children receiving opioids for five or more days, according to a...
Stigma of Substance Use Disorder Varies by Condition, Provider
WEDNESDAY, July 30, 2025 -- Health care provider stigma toward substance use disorder (SUD) varies by condition and provider, according to a study published online July 23 in...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.